A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 Mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD

This study is currently recruiting participants.
Verified November 2012 by GlaxoSmithKline
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01636713
First received: July 5, 2012
Last updated: November 15, 2012
Last verified: November 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2013
  Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)